Print page
Email page
Download PDF
« Previous Release | Next Release »
REDWOOD CITY, Calif., Sep 18, 2009 (GlobeNewswire via COMTEX News Network) -- Threshold Pharmaceuticals, Inc. (Nasdaq:THLD) today announced a presentation of clinical trial results on its hypoxia-activated prodrug, TH-302. The presentation will take place at the Joint 15th Congress of the European CanCer Organisation (ECCO) and the 34th Congress of the European Society for Medical Oncology (ESMO) being held September 20 to 24, 2009, in Berlin, Germany.
The clinical trial results will be outlined in detail in the following poster presentation:
Multi-arm Phase IB study of TH-302 in combination with gemcitabine, docetaxel or pemetrexed, Borad et al., Monday, September 21 from 9:00am - 12:00pm (abstract 1226).
Copies of the poster may be obtained after the poster session by calling the Company.
About Threshold Pharmaceuticals
Threshold is a biotechnology company focused on the discovery and development of drugs targeting Tumor Hypoxia, the low oxygen condition found in microenvironments of most solid tumors. This approach offers broad potential to treat most solid tumors. By selectively targeting tumor cells, we are building a pipeline of drugs that hold promise to be more effective and less toxic to healthy tissues than conventional anticancer drugs. For additional information, please visit our website (www.thresholdpharm.com).
This news release was distributed by GlobeNewswire, www.globenewswire.com
SOURCE: Threshold Pharmaceuticals, Inc.
CONTACT: Threshold Pharmaceuticals, Inc. Denise T. Powell, Sr. Director, Corporate Communications 650-474-8206 dpowell@thresholdpharm.com
(C) Copyright 2009 GlobeNewswire, Inc. All rights reserved.
News Provided by COMTEX